The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Abstract
CONTEXT: Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion, and weight loss is a consistent associated finding. OBJECTIVES: Our objectives were to confirm weight loss with dapagliflozin and establish through body composition measurements whether weight loss is accounted for by changes in fat or fluid components. DESIGN AND SETTING: This was a 24-wk, international, multicenter, randomized, parallel-group, double-blind, placebo-controlled study with ongoing 78-wk site- and patient-blinded extension period at 40 sites in five countries. PATIENTS: Included were 182 patients with T2DM (mean values: women 63.3 and men 58.6 yr of age; hemoglobin A1c 7.17%, body mass index 31.9 kg/m2, and body weight 91.5 kg) inadequately controlled on metformin. INTERVENTION: Dapagliflozin 10 mg/d or placebo was added to open-label metformin for 24 wk. MAIN OUTCOME MEASURES: Primary endpoint was total body weight (TBW) change from baseline at wk 24. Key secondary endpoints were waist circumference and dual-energy x-ray absorptiometry total-body fat mass (FM) changes from baseline at wk 24, and patient proportion achieving body weight reduction of at least 5% at wk 24. In a subset of patients, magnetic resonance assessment of visceral adipose tissue (VAT) and sc adipose tissue (SAT) volume and hepatic lipid content were also evaluated. RESULTS: At wk 24, placebo-corrected changes with dapagliflozin were as follows: TBW, -2.08 kg [95% confidence interval (CI)=-2.84 to -1.31; P<0.0001]; waist circumference, -1.52 cm (95% CI=-2.74 to -0.31; P=0.0143); FM, -1.48 kg (95% CI=-2.22 to -0.74; P=0.0001); proportion of patients achieving weight reduction of at least 5%, +26.2% (95% CI=15.5 to 36.7; P<0.0001); VAT, -258.4 cm3 (95% CI=-448.1 to -68.6; nominal P=0.0084); SAT, -184.9 cm3 (95% CI=-359.7 to -10.1; nominal P=0.0385). In the dapagliflozin vs. placebo groups, respectively, serious adverse events were reported in 6.6 vs. 1.1%; events suggestive of vulvovaginitis, balanitis, and related genital infection in 3.3 vs. 0%; and lower urinary tract infections in 6.6 vs. 2.2%. CONCLUSIONS: Dapagliflozin reduces TBW, predominantly by reducing FM, VAT and SAT in T2DM inadequately controlled with metformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
The prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Grundy, S. M. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.151092 · Cited by 1,616
de Koning, L., Merchant, A. T., Pogue, J., & Anand, S. S. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm026 · Cited by 1,073
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 873
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 725
Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634
Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629
Flagged first, then by citations
Research works printed but not linked: 1
- Tang, 2003, The financing burden of treatment of diabetes-II and its symptom in urban China., Chin Health Econ, 12, 21
Cited by
Sorted by citations
Items 501–600 of 864
Therapeutic developments in metabolic dysfunction-associated fatty liver disease
Shi, Y., & Fan, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002091 · Cited by 14
Katakami, N., Mita, T., Yoshii, H., Shiraiwa, T., Yasuda, T., Okada, Y., Kurozumi, A., Hatazaki, M., Kaneto, H., Osonoi, T., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01879-4 · Cited by 13
Malandris, K., Papandreou, S., Avgerinos, I., Karagiannis, T., Paschos, P., Michailidis, T., Liakos, A., Bekiari, E., Sinakos, E., & Τσάπας, Α. (2023) · HORMONES · doi:10.1007/s42000-023-00493-z · Cited by 13
Dapagliflozin: A new hope for the therapeutic treatment of type 2 diabetes mellitus
Maksud, N., Bera, S., Naim, M. J., & Alam, O. (2024) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2024.100167 · Cited by 14
New Treatments for Type 2 Diabetes: Cardiovascular Protection Beyond Glucose Lowering?
Jayawardene, D., Ward, G. M., O'Neal, D. N., Theverkalam, G., MacIsaac, A. I., & MacIsaac, R. J. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.05.007 · Cited by 13
Tofogliflozin: the road goes ever on
Pafili, K., & Παπάνας, Ν. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.916278 · Cited by 13
Yang, X., Lin, Y., Xu, G., Chen, Y., Zhou, Y., Sun, J., & Li, L. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s304164 · Cited by 13
Sakamoto, M., Goto, Y., Nagayama, A., Yano, M., Sato, S., Tajiri, Y., & Nomura, M. (2021) · Diabetology International · doi:10.1007/s13340-021-00512-7 · Cited by 12
The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
Tilinca, M. C., Tiucă, R. A., Ţilea, I., & Varga, A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121249 · Cited by 15
Zheng, H., Sigal, R. J., Coyle, D., Bai, Z., Johnston, A., Elliott, J., Hsieh, S., Kelly, S., Chen, L., Skidmore, B., et al. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3515 · Cited by 13
Huh, Y., & Kim, Y. S. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01748-1 · Cited by 16
Dapagliflozin modulates the faecal microbiota after myocardial infarction in non‐diabetic mice
Li, Z., Wang, K., Ding, Y., Ma, W., Sun, Y., Liu, X., Qian, L., Li, Y., Hong, J., & Xu, D. (2022) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13727 · Cited by 13
Lapuerta, P., Rosenstock, J., Zambrowicz, B., Powell, D. R., Ogbaa, I., Freiman, J. P., Cefalu, W. T., Banks, P. L., Frazier, K., Kelly, M., et al. (2013) · Clinical Cardiology · doi:10.1002/clc.22125 · Cited by 13
Safe prescribing of metformin in diabetes
Davoren, P. M. (2014) · Australian Prescriber · doi:10.18773/austprescr.2014.001 · Cited by 13
Nojima, T., Matsubayashi, Y., Yoshida, A., Suganami, H., Abe, T., Ishizawa, M., Fujihara, K., Tanaka, S., Kaku, K., & Sone, H. (2020) · Diabetic Medicine · doi:10.1111/dme.14279 · Cited by 13
Thynne, T., & Doogue, M. P. (2013) · Australian Prescriber · doi:10.18773/austprescr.2014.005 · Cited by 13
A Comprehensive Review of Novel Drug–Disease Models in Diabetes Drug Development
Gaitonde, P., Garhyan, P., Link, C., Chien, J. Y., Trame, M. N., & Schmidt, S. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0359-y · Cited by 12
Jankie, S., & Pereira, L. M. P. (2020) · Post Reproductive Health · doi:10.1177/2053369120982753 · Cited by 12
Blood glucose levels and bodyweight change after dapagliflozin administration
Kim, H., Lee, S. H., Lee, H., Yim, H. W., Cho, J., Yoon, K., & Kim, H. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13516 · Cited by 12
The Effective Use of Anti-obesity Medications
Schmitz, S. H., & Aronne, L. J. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.08.003 · Cited by 12
The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on the ‘Forgotten’ Right Ventricle
Qu, L., Duan, X., & Chen, H. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15103 · Cited by 12
SGLT2 inhibitors use in kidney disease: what did we learn?
Akunjee, M., Khosla, S., Nylén, E., & Sen, S. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00034.2025 · Cited by 13
Tobe, K., Suganami, H., & Kaku, K. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12761 · Cited by 12
Vilsbøll, T., Ekholm, E., JOHNSSON, E. K., García‐Sánchez, R., Dronamraju, N., Jabbour, S. A., & Lind, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13981 · Cited by 11
Yang, J. Y., Moon, A. M., Kim, H. H., Pate, V., Barritt, A. S., Crowley, M. J., Buse, J. B., Stürmer, T., & Alexopoulos, A. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107706 · Cited by 12
Zhai, M., Du, X., Changmei, L., & Xu, H. (2021) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2021.703937 · Cited by 12
Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism
Iqbal, N., Ambery, P., Logue, J., Mallappa, A., & Sjöström, C. D. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110669 · Cited by 13
Engeli, S., & Jordan, J. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0374-z · Cited by 12
Schwartz, S. S., & Ahmed, I. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1151774 · Cited by 13
Fioretto, P., & Avogaro, A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1300253 · Cited by 12
Koshizaka, M., Ishikawa, K., Ishikawa, T., Kobayashi, K., Takemoto, M., Horikoshi, T., Shimofusa, R., Takahashi, S., Nagashima, K., Sato, Y., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015766 · Cited by 12
Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
González-Clemente, J. M., García-Castillo, M., Martínez, J. J. G., Jiménez, A., Llorente, I., Matute, E., Pérez, C. T., Izarra, A., & Lecube, A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01280-6 · Cited by 12
Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
Vivian, E. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715607643 · Cited by 13
Yu, H. J., & Woo, V. C. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s117982 · Cited by 12
Park, H. K., Kim, K., Min, K., Sohn, T. S., Jeong, I., Ahn, C. W., Kim, N. H., Park, I. B., Cho, H., Chung, C. H., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15164 · Cited by 11
Satyam, S. M., Bairy, L. K., Rehman, A., Nair, A. A., Farook, M., Binu, N. N., Khan, S., Yehya, M., & Khan, M. M. (2025) · Sci · doi:10.3390/sci7020059 · Cited by 12
Nagai, Y., Ohta, A., Sada, Y., Kato, H., & Tanaka, Y. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1261110 · Cited by 11
Nagai, Y., Fukuda, H., Kawanabe, S., Nakagawa, T., Ohta, A., & Tanaka, Y. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3785 · Cited by 11
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · BMC Medicine · doi:10.1186/s12916-020-01787-4 · Cited by 12
Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors—Fighting Diabetes from a New Perspective
Angelopoulos, T. P., & Doupis, J. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0127-7 · Cited by 12
Mende, C. W., & Katz, A. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0158-y · Cited by 11
Lautsch, D., Alsumali, A., McLeod, E. J., Kuang, Y., He, J. N., Singh, R., Nevo, A., Arnet, U. A., Uyei, J., & Rajpathak, S. N. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00975-y · Cited by 12
SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure in Diabetes?
Verbrugge, F. H., Vangoitsenhoven, R., Müllens, W., der Schueren, B. V., Mathieu, C., & Tang, W. H. W. (2015) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-015-0467-0 · Cited by 11
Takasu, T., Hayashizaki, Y., Hirosumi, J., Minoura, H., Amino, N., Kurosaki, E., & Takakura, S. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00964 · Cited by 11
Diabetes Care for Patients Experiencing Homelessness: Beyond Metformin and Sulfonylureas
Brooks, L. K., Kalyanaraman, N., & Malek, R. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.10.033 · Cited by 11
Hara, K., Sakai, Y., Tajiri, Y., & Nomura, M. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11012 · Cited by 10
Lin, B., Guo, X., Lü, W., Niu, R. L., Zeng, X., Chen, Z., Wu, C., & Liu, C. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176742 · Cited by 10
Gamal, N., Bakly, W. M. S. E., Saad, S. S. T., El-Waseef, D. A. E.-D. A., El‐Shal, A. S., Morsy, W. E., & Magdy, Y. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04136-5 · Cited by 10
Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes
Boyle, L. D., & Wilding, J. P. H. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.831405 · Cited by 10
Self-citationTakeshita, Y., Kanamori, T., Tanaka, T., Kaikoi, Y., Kita, Y., Takata, N., Iida, N., Arai, K., Yamashita, T., Harada, K., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00762-9 · Cited by 10
Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?
Correale, M., Petroni, R., Coiro, S., Antohi, E., Monitillo, F., Leone, M., Triggiani, M., Ishihara, S., Düngen, H., Sarwar, C. M. S., et al. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10107-8 · Cited by 10
Althobaiti, F. M., Alsanosi, S., Falemban, A. H., Alzahrani, A. R., Fataha, S. A., Salih, S. O., Alrumaih, A. M., Alotaibi, K. N., Althobaiti, H. M., Alghamdi, S., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164769 · Cited by 10
Nashar, K., & Khalil, P. (2022) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s234282 · Cited by 10
Lv, J., Guo, L., Wang, R., & Chen, J. (2023) · Kidney Diseases · doi:10.1159/000530395 · Cited by 12
Wan, J., Wu, P., Huang, J., Huang, S., Huang, Q., & Tang, X. M. (2023) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-023-03637-w · Cited by 10
Kheiwa, A., Ssembajjwe, B., Chatta, P., Nageotte, S. J., & Abramov, D. (2024) · International Journal of Cardiology Congenital Heart Disease · doi:10.1016/j.ijcchd.2024.100495 · Cited by 10
Wang, L., Wang, H., Liu, Q., Hua, W.-C., & Li, C. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.002 · Cited by 10
Chen, J., Peng, Y., Chen, C.-S., Tseng, C., Chen, P.-C., Lee, T.-I., Lu, Y.-C., Yang, Y., Lin, C., Hung, Y.-J., et al. (2020) · PeerJ · doi:10.7717/peerj.9998 · Cited by 10
Influence of modern antidiabetic therapy on body weight in patients with type 2 diabetes mellitus
Салухов, В. В., Ilyinskaya, Т. A., & Minakov, A. A. (2022) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2022-11-1-39-52 · Cited by 12
Maranghi, M., Carnovale, A., Durante, C., Tarquini, G., Tiseo, G., & Filetti, S. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.986457 · Cited by 10
Ferreira‐Hermosillo, A., Molina-Ayala, M., Molina-Guerrero, D., Garrido-Mendoza, A. P., Ramírez‐Rentería, C., Mendoza‐Zubieta, V., Espinosa-Cárdenas, E., & Mercado, M. (2020) · Trials · doi:10.1186/s13063-020-4121-x · Cited by 15
An evaluation of empagliflozin and it’s applicability to hypertension as a therapeutic option
Herat, L. Y., Matthews, V. B., Magno, A. L., Kiuchi, M. G., Carnagarin, R., & Schlaich, M. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1751815 · Cited by 10
Chinese Guidelines for Medical Nutrition Therapy for Patients with Diabetes (2022 Edition).
(2024) · PubMed Central · doi:10.6133/apjcn.202406_33(2).0001 · Cited by 9
Raja, A., Dogar, M., Raja, S., Shuja, M. H., Amin, S. B., Khelani, M., Fatima, U., Soomro, A., Habiba, A., Mustafa, I., et al. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04412-x · Cited by 10
Xu, L., Wu, Y., Li, J., Ding, Y., Chow, J., Li, L., Liu, H., Wang, Z., Gong, T., Li, Y., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-088687 · Cited by 11
Yang, S., Hu, Q., Liu, K., Xiao, B., Zhang, B., & Su, N. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1551390 · Cited by 9
Repurposing metabolic drugs as anti-inflammatory agents
Hogan, A. E., Davis, C., Jenkins, B., Jones, N., & O'Shea, D. B. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.07.003 · Cited by 14
Gamil, N. M., Fattah, M. A. A. E., Ahmed, M. A. E., Maklad, Y. A., el Din, A. A. G., & Eid, N. I. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22451 · Cited by 9
Varshney, A., & Rawat, R. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20230090 · Cited by 9
Loria, F., Mone, P., Rispoli, A., Fonzo, R. D., Masarone, D., Mancusi, C., Correale, M., Vitullo, A., Granatiero, M., Mazzeo, P., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02515-5 · Cited by 9
Roy, S., & Majumder, A. (2019) · Cureus · doi:10.7759/cureus.4674 · Cited by 9
SGLT2 inhibitors: a new pillar of the heart failure regimen
DeSa, T. B., & Gong, T. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2204133 · Cited by 10
Impact of Newer Medications for Type 2 Diabetes on Body Weight
Pedersen, S. D. (2013) · Current Obesity Reports · doi:10.1007/s13679-012-0045-4 · Cited by 10
Ji, L., Mishra, M., & Geest, B. D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041092 · Cited by 8
Li, Y., Tang, H., Guo, Y. M., Shao, H., Kimmel, S. E., Bian, J., Schatz, D., & Guo, J. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1379251 · Cited by 8
Battistoni, I., Pongetti, G., Falchetti, E., Giannini, I., Olivieri, R., Gioacchini, F. L. G., Bonelli, P., Contadini, D., Scappini, L., Flori, M., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123522 · Cited by 8
Neff, L. M., Broder, M. S., Beenhouwer, D. O., Chang, E., Papoyan, E., & Wang, Z. W. (2017) · Clinical Obesity · doi:10.1111/cob.12213 · Cited by 8
Jia, H., Bao, P., Yao, S., Zhang, X., Mu, J., Hu, G., Du, M., Chu, C., Zhang, X., Wang, L., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01301-2 · Cited by 9
Ah, B., & Orme, M. E. (2014) · Internal Medicine Open Access · doi:10.4172/2165-8048.s6-006 · Cited by 8
Parker, E. D., Wittbrodt, E. T., McPheeters, J., & Frías, J. P. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13502 · Cited by 8
Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy
Iacobellis, G., Basilico, S., & Malavazos, A. E. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_577 · Cited by 8
Garg, D. U. K., Agrawala, R. K., Akbar, S., Biswas, K., Modhugu, N. R., Warrier, S. B., Scientific Services, U. P. L., Prasad, A., Scientific Services, U. P. L., Birla, A., et al. (2023) · International Journal of Current Science Research and Review · doi:10.47191/ijcsrr/v6-i3-19 · Cited by 8
Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
Cho, H. A., Jung, Y. L., Lee, Y. H., Lee, Y. C., Lee, J. E., Lee, S. J., Jeong, S. J., & Kim, C. H. (2017) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2017.26.2.107 · Cited by 8
Boutari, C., Pοlyzos, S. A., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.03.007 · Cited by 8
Kamalinia, S., Josse, R. G., Donio, P. J., Leduc, L., Shah, B. R., & Tobe, S. W. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.100 · Cited by 7
Iwahashi, Y., Hirose, S., Nakajima, S., Seo, A., Takahashi, T., & Tamori, Y. (2016) · Diabetology International · doi:10.1007/s13340-016-0295-6 · Cited by 7
Chandrasekar, B., Mummidi, S., DeMarco, V. G., & Higashi, Y. (2023) · Mediators of Inflammation · doi:10.1155/2023/6112301 · Cited by 7
Visceral adipose tissue and risk of diabetic nephropathy: A Mendelian randomization study
Tao, M., Zhou, G., Liu, J., He, M., Luo, X., Wang, C., & Zhang, L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111586 · Cited by 8
Metabolic effects of SGLT2i and metformin on 3-hydroxybutyric acid and lactate in db/db mice
Harada, M., Han, S., Shi, M., Ge, J., Yu, S., Adam, J., Adamski, J., Scheerer, M. F., Neschen, S., de Angelis, M. H., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130962 · Cited by 7
Wang, S., Zhang, Y., Balati, A., Li, B., Dai, L., & Yu, D. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf016 · Cited by 6
Lim, S. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13696 · Cited by 7
CVOTs: What did the endocrinologist learn?
Valensi, P. E., & Prévost, G. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107947 · Cited by 6
Tanaka, A., Shimabukuro, M., Teragawa, H., Okada, Y., Takamura, T., Taguchi, I., Toyoda, S., Tomiyama, H., Ueda, S., Higashi, Y., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01352-0 · Cited by 7
Xu, X., Xu, W., Zhuo, Q., & Yan, Y. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-22-121 · Cited by 7
Hockings, P. D., Saeed, N., Simms, R., Smith, N. A. S., Hall, M. G., Waterton, J. C., & Sourbron, S. P. (2020) · Advances in magnetic resonance technology and applications · doi:10.1016/b978-0-12-817057-1.00002-0 · Cited by 10
Guo, L., Wang, J., Li, L., Yuan, L., Chen, S., Wang, H., Li, T., Qi, L., & Hong, Y. (2023) · BMC Medicine · doi:10.1186/s12916-023-02906-7 · Cited by 7
Sethi, B. K., Sahay, R. K., TIWASKAR, M. H., Negalur, V. B., Dhediya, R., Gaurav, K., Rathod, R., Kotak, B., Dhanaki, G. D., & Shah, S. P. (2023) · Drugs - Real World Outcomes · doi:10.1007/s40801-023-00398-8 · Cited by 7
Kouzu, H., Yano, T., Katano, S., Kawaharata, W., Ogura, K., Numazawa, R., Nagaoka, R., Ohori, K., Nishikawa, R., Ohwada, W., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14872 · Cited by 7
Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin
Brooks, A. D., Salvo, M. C., & Thacker, S. M. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s59169 · Cited by 7
Efficacy and Safety of Canagliflozin as Add-On Therapy to Metformin in Type 2 Diabetes
Battise, D. M. (2014) · Clinical Diabetes · doi:10.2337/diaclin.32.2.81 · Cited by 7
Metadata
- Authors
- Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S.
- Affiliations
- Karolinska University Hospital (SE)
- Uppsala University Hospital (SE)
- Aintree University Hospital (GB)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
- Corresponding author
- Bolinder, Jan
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-03-01
- Volume
- 97
- Issue
- 3
- Pages
- 1020-1031
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2167245776
- Cited by
- 867
- References
- 36
- Citations by year
- 2026: 34 · 2025: 41 · 2024: 51 · 2023: 76 · 2022: 76 · 2021: 70 · 2020: 85 · 2019: 54 · 2018: 53 · 2017: 72 · 2016: 62 · 2015: 53 · 2014: 79 · 2013: 42 · 2012: 17
- FWCI
- 48.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, weight loss, body composition, fat mass, visceral adipose tissue, subcutaneous adipose tissue, hepatic fat content, metformin, inadequate glycemic control, waist circumference, fluid balance, urinary glucose excretion, glycemic control
- MeSH terms
- Adipose Tissue, Adult, Aged, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucosides, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Body Mass Index, Treatment Outcome, Body Fat Distribution, Sodium-Glucose Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
